Ensartinib Treatment for Rare Nonclassical ALK Fusion Lung Adenocarcinoma With Brain Metastasis
ONCOLOGY · 10.09.2026 · 40 (7)
DOI: 10.46883/2026.25921241 ↗Kurz gefasst
Fallbericht in der Zeitschrift ONCOLOGY, online erschienen am 10.09.2026. Verfasst von Hong Zheng Mm und 1 weiteren Autor:innen. Hauptthemen laut MEDLINE: Brain Neoplasms, Lung Neoplasms, Anaplastic Lymphoma Kinase, Adenocarcinoma of Lung. Die Arbeit nennt 22 Literaturangaben.
Abstract (Originalsprache)
ALK rearrangements are uncommon but actionable oncogenic drivers in non–small cell lung cancer. STRN-ALK fusions are rare among the nonclassical ALK fusion types, and they pose problems diagnostically and therapeutically. A 50-year-old woman had a 2-year history of cough, sputum, and wheeze. Initial workup revealed a severe mixed ventilatory defect, and imaging demonstrated left lung obstruction with mediastinal lymphadenopathy. Bronchoscopy confirmed mucinous adenocarcinoma, and molecular testing revealed a rare STRN-ALK fusion. Because of the patient’s clinical deterioration and concurrent brain metastases diagnosis, ensartinib was started in conjunction with chemotherapy. The patient had a significant improvement in symptoms, including weight gain. Imaging showed a reduction in total tumor burden and no new lesions on follow-up. The results suggested that ensartinib provided central nervous system stability and long-term tumor control. This is unlike prior descriptive accounts of patients with STRN-ALK fusion lung adenocarcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Hong Zheng Mm, & XiaoJiu Zha Mm (2026). Ensartinib Treatment for Rare Nonclassical ALK Fusion Lung Adenocarcinoma With Brain Metastasis. ONCOLOGY, 40(7). https://doi.org/10.46883/2026.25921241
Vancouver
Hong Zheng Mm, XiaoJiu Zha Mm. Ensartinib Treatment for Rare Nonclassical ALK Fusion Lung Adenocarcinoma With Brain Metastasis. ONCOLOGY. 2026;40(7). doi:10.46883/2026.25921241
BibTeX
@article{HongZhengMm2026,
author = {Hong Zheng Mm and XiaoJiu Zha Mm},
title = {Ensartinib Treatment for Rare Nonclassical ALK Fusion Lung Adenocarcinoma With Brain Metastasis},
journal = {ONCOLOGY},
year = {2026},
volume = {40},
number = {7},
doi = {10.46883/2026.25921241}
}
EUVIMED